HER2/neu-specific antibodies and methods of using same
US11028183B2 · kind B2 · utility
2Cited by
65References
38Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 10, 2018 |
| Grant date | Jun 8, 2021 |
| Priority date | — |
| Expiry date | Dec 26, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention relates to antibodies that specifically bind HER2/neu, and particularly chimeric 4D5 antibodies to HER2/neu, which have reduced glycosylation as compared to known 4D5 antibodies. The invention also relates to methods of using the 4D5 antibodies and compositions comprising them in the diagnosis, prognosis and therapy of diseases such as cancer, autoimmune diseases, inflammatory disorders, and infectious disease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.